Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm extension study of regorafenib (Stivarga) in prior Bayer regorafenib trial participants
2018-003650-24Phase 2Unknown
- Sponsor
- Bayer
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in renal cell carcinoma (RCC), sponsored by Bayer. Primary endpoint: Frequency and severity of SAEs and protocol-specified AEs. Status: unknown.
02
Drugs
regorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2018-003650-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003650-24.